PRP and Exosome Products: Why No Two Clinics Match
Why do PRP and exosome products vary so much between clinics?
Two clinics can print the same words on a price list and hand you preparations that share almost nothing beyond the label. PRP names a process, not a formulation, and exosomes names a category of particle, not a standardized product, so there's no fixed recipe sitting behind either term. That's why the useful question is never whether a clinic offers the treatment, but what system they run and what it actually produces.
| What Varies | Platelet Preparations | Purchased Vesicle Vials |
|---|---|---|
| Who controls the output | The clinic, at the chairside | A third-party supplier, upstream |
| Biggest variables | Draw volume, spin count, leukocyte handling, activation | Source tissue, isolation method, purity, cold chain |
| Measured spread | Roughly 0.5x to 10x your baseline platelet count | Particle counts rarely verified independently |
| Oversight category | Autologous, single procedure | Manufactured allogeneic biologic, none approved for hair |
Neither term names a standardized product, since published comparisons of commercial platelet systems report final concentrations from roughly half of baseline to nearly ten times baseline, while exosome vials differ by source tissue, isolation method and purity before a clinic ever opens the box.
What actually differs between one clinic's platelet-rich plasma preparation and another's?
Four numbers carry most of the distance between two preparations, and you can ask for every one of them. Concentration gets the headline, but volume quietly doubles or halves your dose without changing the advertised multiple. Underneath all of it sits your own platelet count that day, which drifts with hydration, sleep, recent illness and medication.
- Platelet concentration: Reported outputs run from about half baseline to ten times baseline.
- Leukocyte content: Leukocyte-rich formulas keep neutrophils and monocytes; leukocyte-poor ones exclude them.
- Delivered volume: Four milliliters at five times baseline carries twice the platelets of two.
- Activation state: Calcium or thrombin up front, or tissue contact after injection.
Platelet concentration, leukocyte content, delivered volume and activation state account for most of the difference between two preparations, and because dose is concentration multiplied by volume, four milliliters at five times baseline delivers twice the platelet load of two milliliters at the same concentration.
How do different centrifuge systems and single-use kits change what ends up in the syringe?
Hardware is the biggest single lever on what lands in the syringe, and the ladder runs from a plain gel tube spun in a shared lab centrifuge up to a sealed dual-spin device on a programmed cycle. The gap between those two isn't marketing; it's the difference between a modest concentration and the high multiples you see advertised. Treat the marketed multiple with some caution too, since vendor figures usually come from healthy donor blood and a trained operator under ideal conditions.
| Criteria | Gel-Separator Tube | Closed Dual-Spin Device |
|---|---|---|
| Spin stages | One | Two, soft then hard |
| Typical output | Modest concentration, most white cells excluded | Higher concentration, leukocyte content selectable |
| Operator sensitivity | Low, little judgement required | High, concentrated at the harvest |
| Consumable cost | Lowest per treatment | Several times higher per session |
A single-spin gel-separator tube yields a modest platelet concentration at the lowest consumable cost, while a closed dual-spin device running a validated cycle produces the higher concentration factors and tighter run-to-run consistency at several times the cost per session.
Why is there no agreed standard for reporting what a regenerative preparation contains?
Plenty of classification systems exist for describing what a preparation contains, and they largely agree on which variables matter. Almost none of them reach you, and the reason is unglamorous: nobody is required to use one.
No classification standard is enforced in this field, because regulators don't require one for autologous preparations, journals apply reporting rules inconsistently and payers rarely fund the treatment, which leaves every clinic to document its own output voluntarily.
What regulatory status do exosome-based products hold, and how does that shape what a clinic can obtain?
Regulatory posture explains more of the exosome spread than any technical detail does. Your own blood, drawn, spun and returned in a single sitting, sits outside the cells-and-tissues framework entirely, while a donor-derived vial that was manufactured, banked and shipped lands squarely in drug and biologic territory. No exosome product has been approved for hair restoration, so everything on the market reaches a clinic through some other door.
| Criteria | Autologous Platelet Preparation | Purchased Exosome Vial |
|---|---|---|
| Material source | Your own blood | A screened donor's tissue |
| Processing | Single procedure, same visit | Manufactured, banked, shipped |
| Approval status | No product approval required | None approved for hair restoration |
| Paperwork you can ask for | Device, protocol and analyzer readings | A supplier's certificate of analysis |
No exosome product has been approved for hair restoration in the United States, so vials reach clinics under research-use-only, cosmetic or wellness labeling, and a supplier's certificate of analysis is a commercial document rather than a regulatory guarantee.
How much does the person drawing and processing the sample affect the finished product?
Most people assume the machine makes the product. Two clinics running identical equipment still hand out different preparations, and the gap is entirely human: how your blood was drawn, how long it sat, and how much of the platelet layer got lifted off.
- The draw: A traumatic stick or long tourniquet time starts activating platelets in the tube.
- The wait: A sample sitting at room temperature while the room turns over keeps degrading.
- The spin: A hand-set generic centrifuge drifts where a programmed cycle repeats.
- The harvest: Take too little and the dose drops; take too much and plasma or red cells come along.
- The injection: Depth, spacing and volume per site decide whether the product reaches your follicles.
The harvest, where a technician draws off the platelet layer after the spin, is the most operator-dependent moment in the process and can swing the delivered platelet count widely between two people working at the same bench with the same device.
What does the source material of an exosome product tell you about what is in the vial?
A vial's origin decides its cargo, and origins differ enormously. Most commercial products come from mesenchymal stromal cells cultured from birth tissue, with adipose and bone-marrow lines also circulating and plant-derived preparations sitting in a marketing niche of their own. Two labels reading exosome can describe genuinely different contents.
- Source tissue: Umbilical cord, Wharton's jelly, amniotic membrane, placenta, adipose or marrow.
- Isolation method: Ultracentrifugation, chromatography, precipitation and filtration trade purity against yield.
- Particle count: Counts objects in a size range, so debris inflates the number.
- Cold chain: Deep-freeze storage, with freeze-thaw cycling quietly degrading what you're injecting.
A supplier's headline particle count measures objects in a size range rather than functional vesicles, so purity against total protein, marker confirmation of vesicle identity and an unbroken cold chain say far more about a vial's contents than the billions or trillions printed on its label.
How do supplier pricing and purchasing decisions influence which product a clinic offers?
Follow the consumable and most of the variation explains itself. When two clinics quote you a similar price, the whole spread between a cheap tube and a manufactured vial comes out of margin, and margin pressure pushes on the input rather than on the number you're quoted.
Price carries almost no information about preparation quality here, because an aggressive quote usually means a cheaper consumable while a premium quote reflects positioning and overhead as readily as it does a better product.
What risk does a patient take on when the composition of an injected product is unverified?
Two very different risks get talked about as one, and pulling them apart is the whole point. Documented harm belongs overwhelmingly to manufactured donor-derived products, where public health investigations have traced bacterial bloodstream infections in patients across several states back to unapproved umbilical cord material. The second risk isn't danger at all; it's spending six to twelve months of your attention on a weak preparation while a treatable pattern of loss keeps progressing.
Bacterial bloodstream infections in multiple patients across several states have been traced to unapproved umbilical-cord-derived products, a category of harm that autologous platelet preparations don't carry because no donor material enters the patient.
How can someone tell whether a specific preparation has actually been characterized?
Characterization leaves a paper trail, and the absence of one is itself your answer. A practice that has genuinely measured its output can name the device it runs, describe the protocol in spin stages and cycle settings, and give you a number that came off a hematology analyzer instead of a brochure.
- Name the device: Ask which system runs your sample and whether it's single or double spin.
- Pin down the formula: Leukocyte-rich or leukocyte-poor, and how many milliliters get injected.
- Ask for a measured number: An analyzer reading of the finished product, not the manufacturer's factor.
- For a vial, read the certificate: Source tissue, isolation method, purity, sterility, endotoxin, batch number.
- Check any approval claim: The agency's public database settles it in a couple of minutes.
A manufacturer's concentration factor describes what a system achieved in a validation study, while a hematology analyzer reading of the finished preparation describes what this clinic produced from this patient's draw, and only the second reflects operator technique, protocol drift and the people actually being treated.
Why do published results for the same named treatment disagree so widely?
When two studies of the same named treatment land on opposite conclusions, you're usually looking at the same variability problem from another angle. Pooling trials that never reported concentration, leukocyte status or volume produces an answer to a question nobody asked.
- Undescribed preparations: Many reports omit concentration, leukocyte status, activation or delivered volume.
- Mismatched endpoints: Hair density, shaft diameter, global assessment and satisfaction don't convert into each other.
- Protocol spread: Session counts run one to six, intervals two weeks to three months.
- Thin vesicle evidence: Mostly laboratory work, animal models and small uncontrolled series so far.
Platelet therapy for pattern hair loss rests on an inconsistent but substantial base of controlled human trials, while the vesicle evidence remains weighted toward laboratory work, animal models and small uncontrolled case series, so the two options are not equally evidenced.
